Ridker PM - Search Results

1

Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.

Chu AY, Guilianini F, Barratt BJ, Nyberg F, Chasman DI, Ridker PM. Chu AY, et al. Among authors: ridker pm. Circ Cardiovasc Genet. 2012 Feb 1;5(1):58-65. doi: 10.1161/CIRCGENETICS.111.961847. Epub 2012 Jan 9. Circ Cardiovasc Genet. 2012. PMID: 22230323 Clinical Trial.

2

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.

Ridker PM, Glynn RJ, Hennekens CH. Ridker PM, et al. Circulation. 1998 May 26;97(20):2007-11. doi: 10.1161/01.cir.97.20.2007. Circulation. 1998. PMID: 9610529 Clinical Trial.

3

Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.

Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Ridker PM, et al. Circulation. 1998 Aug 25;98(8):731-3. doi: 10.1161/01.cir.98.8.731. Circulation. 1998. PMID: 9727541 Clinical Trial.

4

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Ridker PM, et al. Circulation. 1998 Sep 1;98(9):839-44. doi: 10.1161/01.cir.98.9.839. Circulation. 1998. PMID: 9738637 Clinical Trial.

5

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.

Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Ridker PM, et al. Circulation. 1999 Jul 20;100(3):230-5. doi: 10.1161/01.cir.100.3.230. Circulation. 1999. PMID: 10411845 Clinical Trial.

6

Hormone replacement therapy and increased plasma concentration of C-reactive protein.

Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Ridker PM, et al. Circulation. 1999 Aug 17;100(7):713-6. doi: 10.1161/01.cir.100.7.713. Circulation. 1999. PMID: 10449692

7

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Ridker PM, et al. Circulation. 2000 Apr 18;101(15):1767-72. doi: 10.1161/01.cir.101.15.1767. Circulation. 2000. PMID: 10769275

8

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.

Ridker PM, Rifai N, Lowenthal SP. Ridker PM, et al. Circulation. 2001 Mar 6;103(9):1191-3. doi: 10.1161/01.cir.103.9.1191. Circulation. 2001. PMID: 11238259 Clinical Trial.

9

High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.

Ridker PM. Ridker PM. Circulation. 2001 Apr 3;103(13):1813-8. doi: 10.1161/01.cir.103.13.1813. Circulation. 2001. PMID: 11282915

10

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Ridker PM, et al. N Engl J Med. 2001 Jun 28;344(26):1959-65. doi: 10.1056/NEJM200106283442601. N Engl J Med. 2001. PMID: 11430324 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,162 results

Search Page

Filters